Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Medpace Holdings Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.4 (market cap $41.13B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 2.4× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Medpace Holdings Inc for 14 Days on average.
| IEF | MEDP | |
|---|---|---|
Market Cap | $41.13B | $16.82B |
Volume | 10,340,382 | 223,093 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $630.19 |
52-Week Low | $88.92 | $393.42 |
Typical Hold Time | 108 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF is trading at $89.40, up 0.33% with a bearish technical signal. The ETF shows neutral oscillators but bearish moving averages, with key support at $89 and resistance at $90. Recent dividend payments of $0.31-$0.33 per share provide income, while financial ratios remain unavailable. Market sentiment reflects defensive positioning amid Treasury yield volatility.
Outlook remains cautious due to technical bearishness and bond market pressures. Opportunities include income from dividends and potential stability in defensive portfolios. Risks include continued bond market volatility and macroeconomic uncertainty affecting Treasury yields.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
